Amgen (AMGN) said Friday that a phase 3 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung cancer met its primary endpoint at a planned interim analysis.
The biopharmaceutical company said the data show that Imdelltra demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.
Amgen said the randomized open-label clinical trial is evaluating the efficacy and safety of Imdelltra as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。